Ignite Creation Date:
2024-05-05 @ 5:17 PM
Last Modification Date:
2024-10-26 @ 9:30 AM
Study NCT ID:
NCT00426296
Status:
UNKNOWN
Last Update Posted:
2007-11-01
First Post:
2007-01-23
Brief Title:
SHARE Simple HAART With Abacavir Reyataz and Epivir
Sponsor:
Clinical Alliance for Research Education - Infectious Diseases LLC
Organization:
Clinical Alliance for Research Education - Infectious Diseases LLC
Study Overview
Official Title:
An Open-Label Multicenter Study to Evaluate the Efficacy and Safety of a Fixed-Dose Combination of Abacavir 600 mgLamivudine 300 mg Once-Daily in Combination With Atazanavir 300 mg Ritonavir 100 mg Once-Daily in Antiretroviral-Naïve HIV-1 Infected Subjects With Continuing Evaluation of AbacavirLamivudine Plus Atazanavir 400 mg for Maintenance Over an Additional 48 Weeks
Status:
UNKNOWN
Status Verified Date:
2007-10
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
SHARE Simple HAART with Abacavir Reyataz and Epivir
Detailed Description:
Open-label multicenter study of ABC3TC ATV in subjects who have completed at least 24 weeks of treatment on ABC3TCATVRTV as their first line regimen and have plasma HIV-1 RNA 50 copiesmL at entry
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None